Follow-up: Progenics Pharmaceuticals downgraded at Needham
As reported previously, Needham downgraded Progenics Pharmaceuticals to Hold from Buy. The analyst views the loss of Wyeth (WYE) as a Relistor partner as an overall negative and believes it will likely result in further delays in its development and commercialization. :theflyonthewall.com
News For PGNX From The Last 14 Days
Check below for free stories on PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
